Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Essex Bio-Technology ( (HK:1061) ) has shared an announcement.
Essex Bio-Technology Limited has received approval from the National Medical Products Administration for the commercialization of its multi-dose Diquafosol Sodium Eye Drops in the People’s Republic of China. This product, aimed at treating dry eye syndromes, expands the company’s ophthalmic treatment options in the region, potentially strengthening its market position and offering more choices to patients.
More about Essex Bio-Technology
Essex Bio-Technology Limited operates in the biotechnology industry, focusing on the development and commercialization of biopharmaceutical products. The company primarily offers treatments for ophthalmic diseases and conditions, with a market focus on the People’s Republic of China.
Average Trading Volume: 1,597,517
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.95B
See more data about 1061 stock on TipRanks’ Stock Analysis page.